Skip to main content
Top
Published in: Endocrine 2/2016

01-08-2016 | Editorial

Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications?

Authors: Carmine Gazzaruso, Mariangela Fodaro, Adriana Coppola

Published in: Endocrine | Issue 2/2016

Login to get access

Excerpt

Diabetes mellitus is an epidemic, chronic condition characterized by increased morbidity, disability, and mortality because of frequent complications [1]. Complications mainly affect the heart, brain, limbs, eyes, nerves, and kidneys; in addition, most of the diabetic patients die from cardiovascular events [1]. A strict glycemic control, together with the appropriate management of any associated risk factor, such as hypertension, dyslipidemia, obesity, and thrombotic risk, can significantly decrease the complications of diabetes [24]. The tight control of diabetes and other risk factors is usually obtained by treatments with specific medications [24]. Therapeutic patient education (TPE) is considered a central element of the management of diabetes [1]. Many studies have shown that a structured TPE is able to determine a significant improvement in several clinical, lifestyle, and psycho-social outcomes in people suffering from diabetes [1]. However, there are a few data regarding the potential direct and indirect role that a structured TPE may have in the prevention of diabetic complications. An early study suggested that complications can occur about 4 times more frequently in diabetic people with no education [5]. In the present issue of Endocrine, Wong and colleagues have shown that a structured TPE, called patient empowerment programme (PEP), can determine a lower incidence rate of all-cause mortality and first macrovascular and microvascular events [6]. Nevertheless, an additional benefit was not observed in obese diabetic subjects who participated in a specific weight management program [6]. However, the present study has confirmed previous data on the effectiveness of PEP in decreasing complications and mortality in people with diabetes [7, 8]. In the recent long-term study with a follow-up of about 13 years, a structured personal care delivered by general practitioners to 1381 newly diagnosed type 2 diabetic patients was able to reduce mortality and morbidity in women but not in men [9]. These findings should open an active debate and stimulate new research on the decisive role that TPE can play in the prevention of diabetic complications and in the reduction of mortality. On the other hand, the American Association of Diabetes Educators has suggested that diabetes self-management education and support should be an essential tool to reduce the risks of complications and death [10]. In other words, a structured TPE should be always added to medications not only to better manage the disease but also to reduce its risks. The new findings suggest some questions: Could TPE improve the impressive results obtained with medications in the prevention of complications and reduction of mortality [2, 1113]? Could TPE modify the results of the trials which failed to show significant differences in the outcomes between intervention and control group [14, 15]? A sure answer does not exist, but we cannot exclude that TPE could give an additional benefit. Indeed, a synergic effect between medications and TPE on the reduction of complications and death can be hypothesized for at least two reasons: (1) both can improve outcomes in an independent manner and therefore the positive effect may be additive; (2) TPE can optimize effects of medications because of an improvement in adherence [16]. However, if we assume that TPE can prevent the complications, other investigations should explain whether the effectiveness of TPE reported in the published studies [1, 69] can be further increased. At the moment, the ideal characteristics of TPE to give the best results in the management of diabetes and in the prevention of its complications are not defined [1, 10]. Therefore, other works are needed to definitively clarify these ideal characteristics: type of PTE (individual or group education, or both), themes, frequency and number of education sessions, contact time between educator and patient, background of educators, use of new technologies [1]. Another intriguing consideration regards the fact that TPE was able to significantly reduce the risks due to diabetes, even if in the above-mentioned studies the program included some of the potential themes of education [69]. So, it is likely that a global, comprehensive education could give better results. Therefore, other investigations should clarify whether the positive impact of TPE on the prevention of diabetic complications can be further increased by including additional themes, such as diabetic foot, sexual health, and peripheral artery disease [1, 1719]. …
Literature
1.
go back to reference A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine (2015). doi:10.1007/s12020-015-0775-7 PubMed A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine (2015). doi:10.​1007/​s12020-015-0775-7 PubMed
2.
go back to reference P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl. J. Med. 348(5), 383–393 (2003)CrossRefPubMed P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl. J. Med. 348(5), 383–393 (2003)CrossRefPubMed
3.
go back to reference D. DeWitt, D.C. Dugdale, W.R. Adam, Nonglycemic targets in diabetes. Med. Clin. N. Am. 99(1), 187–200 (2015)CrossRefPubMed D. DeWitt, D.C. Dugdale, W.R. Adam, Nonglycemic targets in diabetes. Med. Clin. N. Am. 99(1), 187–200 (2015)CrossRefPubMed
4.
go back to reference J.J. Chamberlain, A.S. Rhinehart, C.F. Shaefer Jr, A. Neuman, Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann. Intern. Med. (2016). doi:10.7326/M15-3016 PubMed J.J. Chamberlain, A.S. Rhinehart, C.F. Shaefer Jr, A. Neuman, Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann. Intern. Med. (2016). doi:10.​7326/​M15-3016 PubMed
5.
go back to reference A. Nicolucci, D. Cavaliere, N. Scorpiglione, F. Carinci, F. Capani, G. Tognoni, M.M. Benedetti, A comprehensive assessment of the avoidability of long-term complications of diabetes: a case-control study. SID-AMD Italian Study Group for the Implementation of the St. Vincent declaration. Diabetes Care 19(9), 927–933 (1996)CrossRefPubMed A. Nicolucci, D. Cavaliere, N. Scorpiglione, F. Carinci, F. Capani, G. Tognoni, M.M. Benedetti, A comprehensive assessment of the avoidability of long-term complications of diabetes: a case-control study. SID-AMD Italian Study Group for the Implementation of the St. Vincent declaration. Diabetes Care 19(9), 927–933 (1996)CrossRefPubMed
6.
go back to reference C.K. Wong, W.C. Wong, E.Y. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Macrovascular and microvascular disease in obese patients with type 2 diabetes attending structured diabetes education program: a population-based propensity-matched cohort analysis of Patient Empowerment Programme (PEP). Endocrine (2016). doi:10.1007/s12020-015-0843-z PubMed C.K. Wong, W.C. Wong, E.Y. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Macrovascular and microvascular disease in obese patients with type 2 diabetes attending structured diabetes education program: a population-based propensity-matched cohort analysis of Patient Empowerment Programme (PEP). Endocrine (2016). doi:10.​1007/​s12020-015-0843-z PubMed
7.
go back to reference C.K. Wong, W.C. Wong, A.K. Chan, K.L. Chung, F.W. Chan, C.L.K. Lam, Patient Empowerment programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population-based propensity-matched cohort study. Diabetes Obes. Metab. 17(2), 128–135 (2015)CrossRefPubMed C.K. Wong, W.C. Wong, A.K. Chan, K.L. Chung, F.W. Chan, C.L.K. Lam, Patient Empowerment programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population-based propensity-matched cohort study. Diabetes Obes. Metab. 17(2), 128–135 (2015)CrossRefPubMed
8.
go back to reference C.K. Wong, W.C. Wong, Y.F. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Patient empowerment programme (PEP) and risk of microvascular diseases among patients with type 2 diabetes in primary care: a population-based propensity-matched cohort study. Diabetes Care 38(8), e116–e117 (2015)CrossRefPubMed C.K. Wong, W.C. Wong, Y.F. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Patient empowerment programme (PEP) and risk of microvascular diseases among patients with type 2 diabetes in primary care: a population-based propensity-matched cohort study. Diabetes Care 38(8), e116–e117 (2015)CrossRefPubMed
9.
go back to reference M.O. Krag, L. Hasselbalch, V. Siersma, A.B.S. Nielsen, S. Reventlow, K. Malterud, N. de Fine Olivarius, The impact of gender on long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13 year follow-up study. Diabetologia 59, 275–285 (2016)CrossRefPubMed M.O. Krag, L. Hasselbalch, V. Siersma, A.B.S. Nielsen, S. Reventlow, K. Malterud, N. de Fine Olivarius, The impact of gender on long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13 year follow-up study. Diabetologia 59, 275–285 (2016)CrossRefPubMed
10.
go back to reference D. Kent, G. D’EramoMelkus, P.M. Stuart, J.M. McKoy, P. Urbanski, S.A. Boren, L. Coke, J.E. Winters, N.L. Horsley, D. Sherr, R. Lipman, Reducing the risks of diabetes complications through diabetes self-management education and support. Popul. Health Manag. 16(2), 74–81 (2013)CrossRefPubMed D. Kent, G. D’EramoMelkus, P.M. Stuart, J.M. McKoy, P. Urbanski, S.A. Boren, L. Coke, J.E. Winters, N.L. Horsley, D. Sherr, R. Lipman, Reducing the risks of diabetes complications through diabetes self-management education and support. Popul. Health Manag. 16(2), 74–81 (2013)CrossRefPubMed
11.
go back to reference B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG Outcome Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl. J. Med. 373(22), 2117–2128 (2015)CrossRefPubMed B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG Outcome Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl. J. Med. 373(22), 2117–2128 (2015)CrossRefPubMed
12.
go back to reference UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 352(9131), 837–853 (1998)CrossRef UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 352(9131), 837–853 (1998)CrossRef
13.
go back to reference H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller, CARDS investigators, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 (2004)CrossRefPubMed H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller, CARDS investigators, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 (2004)CrossRefPubMed
14.
go back to reference M. Meier, M. Hummel, Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag. 5, 859–871 (2009)CrossRefPubMedPubMedCentral M. Meier, M. Hummel, Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag. 5, 859–871 (2009)CrossRefPubMedPubMedCentral
15.
go back to reference J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, TECOS Study Group, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New Engl. J. Med. 373(3), 232–242 (2015)CrossRefPubMed J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, TECOS Study Group, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New Engl. J. Med. 373(3), 232–242 (2015)CrossRefPubMed
16.
go back to reference S. Sapkota, J.A. Brien, J. Greenfield, P. Aslani, A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes: impact on adherence. PLoS One 10(2), e0118296 (2015)CrossRefPubMedPubMedCentral S. Sapkota, J.A. Brien, J. Greenfield, P. Aslani, A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes: impact on adherence. PLoS One 10(2), e0118296 (2015)CrossRefPubMedPubMedCentral
17.
go back to reference C. Gazzaruso, A. Coppola, T. Montalcini, E. Baffero, A. Garzaniti, G. Pelissero, S. Collaviti, A. Grugnetti, P. Gallotti, A. Pujia, S.B. Solerte, A. Giustina, Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 41(1), 89–95 (2012)CrossRefPubMed C. Gazzaruso, A. Coppola, T. Montalcini, E. Baffero, A. Garzaniti, G. Pelissero, S. Collaviti, A. Grugnetti, P. Gallotti, A. Pujia, S.B. Solerte, A. Giustina, Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 41(1), 89–95 (2012)CrossRefPubMed
18.
go back to reference C. Gazzaruso, A. Coppola, T. Montalcini, C. Valenti, A. Garzaniti, G. Pelissero, F. Salvucci, P. Gallotti, A. Pujia, C. Falcone, S.B. Solerte, A. Giustina, Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 40(2), 273–279 (2011)CrossRefPubMed C. Gazzaruso, A. Coppola, T. Montalcini, C. Valenti, A. Garzaniti, G. Pelissero, F. Salvucci, P. Gallotti, A. Pujia, C. Falcone, S.B. Solerte, A. Giustina, Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 40(2), 273–279 (2011)CrossRefPubMed
19.
go back to reference C. Gazzaruso, A. Coppola, C. Falcone, C. Luppi, T. Montalcini, E. Baffero, P. Gallotti, A. Pujia, S.B. Solerte, G. Pelissero, A. Giustina, Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. Diabetes Care 36(6), 1720–1725 (2013)CrossRefPubMedPubMedCentral C. Gazzaruso, A. Coppola, C. Falcone, C. Luppi, T. Montalcini, E. Baffero, P. Gallotti, A. Pujia, S.B. Solerte, G. Pelissero, A. Giustina, Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. Diabetes Care 36(6), 1720–1725 (2013)CrossRefPubMedPubMedCentral
20.
go back to reference L. Fisher, R.E. Glasgow, A call for more effectively integrating behavioral and social science principles into comprehensive diabetes care. Diabetes Care 30(10), 2746–2749 (2007)CrossRefPubMed L. Fisher, R.E. Glasgow, A call for more effectively integrating behavioral and social science principles into comprehensive diabetes care. Diabetes Care 30(10), 2746–2749 (2007)CrossRefPubMed
Metadata
Title
Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications?
Authors
Carmine Gazzaruso
Mariangela Fodaro
Adriana Coppola
Publication date
01-08-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0947-0

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.